GenesisAI

GenesisAI

The Global AI Marketplace

Print
Claim My Business
Security Type
Preferred Stock
Min Investment
$500
Location
Miami, FL
Offering Date
September 30, 2021
Expected Close Date
March 30, 2022
Target Raise
$10.00K-$1.40M
Security Price
$2
Valuation
$89,000,000
Website
genesisai.io/

Company Description

Our mission is to build Artificial General Intelligence. We believe we have the most practical approach of doing it: creating a platform that will connect 1000s of expert AI tools together. Our web-platform allows companies to easily deploy their AI tools whilst giving everyone a chance to access high quality AI products. Founded by Harvard alumni, backed by MIT professors, and funded by two renowned Venture Capital firms, GenesisAI is the future of AI!

Key Deal Facts

The future is AI: AI is projected to contribute up-to $15 Trillion to the world economy.
Incredible growth: 19 times; growth of monthly new user registrations on our platform on average.
Elite team: Founded by Harvard alumni. Backed by MIT and Harvard professors. Funded by two distinguished VCs.
Amount Raised : $92,497
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Preferred securities are a type of investment that generally offers some sort of preferred treatment through a dividend or preferred treatment in a liquidation.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments